REG-Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Alvotech has commenced an underwritten public offering of ordinary shares with gross proceeds of approximately $125 million. The offering is concurrent with a private placement to eligible investors in the European Economic Area, with the total proceeds intended to fund biosimilar development, working capital, and general corporate purposes. BofA Securities, Jefferies, and Evercore ISI are acting as joint book-running managers.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.